Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Impacts of the Covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic
The containment of the population in France is a health measure implemented in response to SARS-CoV-2 (Covid-19) infection. For cystic fibrosis, as for many chronic diseases, this disruption is twofold. On the one hand, it affects daily life due to the closure of schools and the introduction of national lockdown, but also the hospital, which has profoundly changed its procedures, which are almost completely focused on the care of patients with Covid-19. This forced transformation was at the expense of its usual role including the management of chronic diseases such as cystic fibrosis. It has an impact on patients' consultations cancelled, rescheduled or replaced by teleconsultations, hospitalisations whether scheduled or during acute exacerbations which are more complicated to organise. Access to treatments is also more difficult (physiotherapy), which can affect compliance. Confinement also profoundly changes the lives of our patients. It changes the way individuals can apprehend their disease and its integration into their everyday life, studies or professional projects. Finally, it is the confrontation with a potentially fatal infection that reminds us of the risks and consequences of a potentially severe chronic disease.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Questionnaire and/or interview | An online questionnaire to assess the quantitative aspect of the impact of lockdown on all areas of the cystic fibrosis patient's health, be it physical, mental or social (using quality of life assessment in particular and interviews in the human and social sciences). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Questionnaire | Behavioral | The study questionnaire was constructed as follows:
|
| Measure | Description | Time Frame |
|---|---|---|
| Cancellation or postponement of consultations by the health professional or patient, | Number of consultations cancelled or postponed by the health professional or patient of consultations (medical and paramedical), | Up to 6 months |
| Patient cancellation of teleconsultations/telecare replacement, | Number of consultations cancelled by the teleconsultation/replacement patient, | Up to 6 months |
| Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled), | Number of consultations cancelled or postponed by the health care institution or by the patient of hospitalizations (acute or scheduled) | Up to 6 months |
| Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration). | Number of patients affected by the change in the modality of administration of antibiotic cures (intravenous instead of intravenous administration). | Up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| The reduction of each of the elements of care provision and health care utilization: | Cancellation or postponement by the patient of consultations (medical or paramedical)
| Up to 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study will be proposed to cystic fibrosis patients residing in France.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Intercommunal hospital of Créteil | Créteil | IDF | 94000 | France | ||
| TROUSSEAU Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36452951 | Derived | Oubaya N, Pombet T, Delestrain C, Remus N, Douvry B, Grenet D, Corvol H, Thouvenin G, Pruliere-Escabasse V, Mounir H, Argoud D, Fretigne C, Costes L, Mackiewicz MP, Jung C, Ahamada L, Lanone S, Maitre B, Begot AC, Epaud R. Impact of the COVID-19 pandemic and associated lockdown measures on the management, health, and behavior of the cystic fibrosis population in France during 2020 (MUCONFIN). Front Public Health. 2022 Nov 14;10:978627. doi: 10.3389/fpubh.2022.978627. eCollection 2022. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Interview | Behavioral | Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire. |
|
|
| The change of modality of administration of antibiotic cures | Intravenous instead of intravenous administration | Up to 6 months |
| Compliance | Questionnaire about taking or not taking treatment during confinement | Up to 6 months |
| Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well) | Scale 0-21 | Up to 6 months |
| Presence or absence of toxic consumption (drug, alcohol) during the lockdown | A questionnaire on the presence or absence of toxic consumption | Up to 6 months |
| Evaluation of the knowledge, experience and social representations of the risk of Covid-19 | Experience and social representations of confinement by cystic fibrosis patients (evaluated by qualitative methods) | Up to 6 months |
| Assessing the role of social inequalities in the consequences of lockdown | Role of social inequalities in the consequences of containment assessed by qualitative methods | Up to 6 months |
| Suspected and/or confirmed Covid-19 in patients with cystic fibrosis. | Prevalence of suspected and/or confirmed Covid-19 infections in patients with cystic fibrosis | Up to 6 months |
| Paris |
| IDF |
| 75012 |
| France |
| FOCH Hospital | Suresnes | IDF | 92150 | France |
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| D007407 | Interviews as Topic |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
Not provided
Not provided